IMPEDIMED LIMITED — Capital/Financing Update 2016

Feb 4, 2016

==> picture [333 x 175] intentionally omitted <==

MARKET RELEASE

5 February 2016

ImpediMed Limited

TRADING HALT

The securities of ImpediMed Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on 9 February 2016 or when the announcement is released to the market.

Security Code: IPD

Lisa Banh

SENIOR ADVISER, LISTINGS COMPLIANCE

20 Bridge Street www.asx.com.au Sydney NSW 2000 Customer service 13 12 79

ASX Compliance Pty Limited ABN 26 087 780 489

==> picture [194 x 44] intentionally omitted <==

5 February 2016

By email : lisa.banh@asx.com.au

Ms Lisa Banh ASX Compliance Pty Ltd 20 Bridge Street SYDNEY NSW 2000

Dear Lisa,

ImpediMed Limited – Request for trading halt under Listing Rule 17.1

ImpediMed Limited ( ImpediMed ) requests a trading halt in its shares from the commencement of trading today, Friday 5 February 2016 until the commencement of trading on Tuesday 9 February 2016.

In accordance with Listing Rule 17.1, I advise that:

• (a) ImpediMed is seeking the trading halt pending the making of an announcement to the market in relation to a proposed capital raising. The price and number of shares which will be issued is yet to be determined;

• (b) ImpediMed is seeking the trading halt to assist in managing its disclosure obligations in relation to the proposed capital raising and maintaining an orderly market in the trading of ImpediMed’s shares and to ensure that trading does not take place in an uninformed market;

• (c) ImpediMed requests that the trading halt last until the earlier of the commencement of trading on Tuesday 9 February 2016 or when ImpediMed makes an announcement to the market concerning the proposed capital raising;

• (d) ImpediMed is not aware of any reason why the trading halt should not be granted.

If you have any further questions, please do not hesitate to contact me.

Yours faithfully

Richard Carreon

Managing Director & CEO

ImpediMed
Limited
ABN
65
089
705
144 Unit
1,
50
Parker
Court,
Pinkenba,
QLD
4008
Australia
•
Tel
+61
(7)
3860-­‐3700
Fax
+61
(7)
3260-­‐1225 www.impedimed.com

For further information contact:

Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImediMed CFO T: +1 (760) 585-2100

Kyahn Williamson, Buchan Investor and Media Relations T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

ImpediMed
Limited
ABN
65
089
705
144 Unit
1,
50
Parker
Court,
Pinkenba,
QLD
4008
Australia
•
Tel
+61
(7)
3860-­‐3700
Fax
+61
(7)
3260-­‐1225 www.impedimed.com